Overview: Myelo-Peroxidase Immunohistochemistry TestIntroduction: The Myelo-Peroxidase Immunohistochemistry Test detects myeloperoxidase (MPO) to diagnose leukemia or lymphomas, causing fatigue or swelling. Aligned with 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected hematopoietic malignancies.
Other Names: MPO IHC Assay, Leukemia/Lymphoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: MPO testing began in the 1980s with leukemia research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects myeloperoxidase to diagnose leukemia or lymphomas, guides treatment, and evaluates patients with fatigue or swelling.
Test Parameters: 1. Myeloperoxidase Protein
Pretest Condition: No fasting required. Collect tissue via bone marrow biopsy or lymph node biopsy. Report history of fatigue, swelling, or bleeding.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, swelling, bleeding, or family history of leukemia or lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect MPO in bone marrow or lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for leukemia or lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive MPO staining suggests acute myeloid leukemia or certain lymphomas, guiding chemotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD34 IHC, flow cytometry, or bone marrow biopsy to confirm leukemia or lymphoma diagnosis.
Test Limitations: Not specific to one malignancy; other conditions may express MPO. Clinical correlation is needed.
References: WHO Hematopathology Guidelines, 2023; Blood, Arber DA, 2022.
